The group said its partner Cognizant will oversee the roll-out of GDm-Health, which will qualify for reimbursement under remote patient monitoring codes introduced by the Centers for Medicare and Medicaid Services.
Diabetes in pregnancy is a common condition that can increase the risk of hypertension and caesarean section in mothers as well as pre-term birth, birth trauma and admission to neonatal intensive care for new-born babies.
Over 20% of pregnancies in the States are affected by diabetes every year.
GDm-Health has the potential to significantly improve the way this treatable condition is managed.
The push into the US follows results from a trial in the UK that demonstrated a reduction in caesarean sections, improvements in blood glucose monitoring adherence and higher satisfaction with care in women using the Sensyne device.
The company is currently wrapping up a pilot of the technology at Jefferson Health, a network of 14 hospitals in the Greater Philadelphia area.
Results are expected to be reported in a peer-reviewed journal early next year.
Sensyne chief executive Lord Drayson said the GDm-Health’s American launch marked a “major milestone” and “key objective” for the financial year.
“Entering the US market will help pregnant women and clinicians in the US manage diabetes in pregnancy, improving outcomes for both mothers and babies,” he added in a statement.